Paclitaxel Hospira

Paclitaxel, the active ingredient in Paclitaxel Hospira, is a antineoplastic agent presented as a sterile lyophilized powder for intravenous infusion use. It treats various malignant neoplasms and is administered under the supervision of oncology specialists.

GNH USA supplies Paclitaxel Hospira as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Paclitaxel is employed across several oncologic indications where microtubule stabilization disrupts tumor cell proliferation: - Breast cancer: improves clinical outcomes by reducing tumor growth. - Ovarian cancer: used in combination regimens to achieve tumor response. - Non‑small cell lung cancer: contributes to disease control as part of multi‑drug protocols. - Kaposi's sarcoma: helps reduce lesion burden in affected patients. - Gastric cancer: incorporated into first‑line treatment strategies. - Pancreatic cancer: used in combination therapy to enhance response rates.

Adverse reactions to Paclitaxel vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white‑blood‑cell count increasing infection risk. - Alopecia: hair loss affecting scalp and body hair. - Peripheral neuropathy: tingling or numbness in extremities. - Nausea and vomiting: gastrointestinal upset common during infusion. - Fatigue: generalized tiredness reported by many patients. - Myalgia: muscle aches and joint discomfort.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: anaphylaxis‑like symptoms requiring immediate medical attention. - Cardiotoxicity: arrhythmias or myocardial ischemia in susceptible individuals. - Severe neutropenic infection: febrile neutropenia with systemic infection signs. - Pulmonary toxicity: interstitial pneumonitis or acute respiratory distress. - Hepatotoxicity: marked elevation of liver enzymes and potential liver injury. - Thromboembolic events: deep‑vein thrombosis or pulmonary embolism.

When handling Paclitaxel Hospira, clinicians must observe several safety measures: - Pre‑medication: administer A           ...   - Monitoring:  ...  ...  - Contra‑indication :  ...  - Pregnancy  :  ...  - Breast   :   - Store at 2-8°C: keep refrigerated   developed 

Paclitax